Newark, NJ, May 13, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the appointment of Mona M. Wahba, MD, MSM, as Senior Vice President for Clinical Development and Clinical Operations.
Dr. Wahba’s impressive background includes her success in creating and implementing high-value strategic vision and clinical development (Phase I-IV), immunology, and nuclear medicine, resulting in global submissions, approvals, launch and growth of ten new products worldwide. She has developed a successful working relationship with health authorities, including the Food and Drug Administration (FDA), which resulted in smooth label negotiations, approvals, and effective promotional materials.
Sanjeev Luther, President and Chief Executive Officer of Rafael Pharmaceuticals, commented, “We are thrilled to welcome Dr. Wahba to our senior team at Rafael Pharmaceuticals. Her successful and rich career has been guided by her deep passion for patients, a quality aligning with our motto, ‘To Save A Life Is To Save A Universe.’ We are confident that Dr. Wahba will provide significant aid in our mission to develop potential treatments for patients with pancreatic cancer, acute myeloid leukemia and other difficult-to-treat cancers.”
Prior to joining Rafael Pharmaceuticals, Dr. Wahba held executive positions in the pharmaceutical industry at both large and small companies, including Pfizer, Bristol-Myers Squibb, Novartis, Bayer, Taiho and Ipsen. She effectively created and led large teams and franchises for maximum performance, including joint ventures and alliances with different organizations.
Dr. Wahba has a medical degree in addition to a master’s degree in leadership and science management. Dr. Wahba is a member of industry-respected organizations including American Society of Clinical Oncology (ASCO), Society of Nuclear Medicine and Molecular Imaging (SNMMI), European Society for Medical Oncology (ESMO) and European Neuroendocrine Tumor Society (ENETS).
About Rafael Pharmaceuticals, Inc.
Rafael Pharmaceuticals, Inc. is a clinical stage company and a leader in the growing field of cancer metabolism-based therapeutics. Rafael’s primary objective is to develop and commercialize innovative, highly selective, well tolerated and highly effective anti-cancer agents by selectively targeting the altered metabolism in cancer cells. Rafael’s first-in-class clinical lead compound, CPI-613®(devimistat), is being evaluated in multiple ongoing/completed Phase I, II, and III clinical studies. CPI-613®(devimistat) has been granted orphan drug designation for the treatment of Pancreatic Cancer, Acute Myeloid Leukemia (AML), Peripheral T-Cell Lymphoma (PTCL), Burkitt Lymphoma and Myelodysplastic Syndromes (MDS). Rafael Pharmaceuticals is an affiliate of Rafael Holdings, Inc. (NYSE AMERICAN: RFL). For more information, visit http://www.rafaelpharma.com/.
Safe Harbor Statement
This press release contains forward-looking statements. These statements relate to future events or the company’s future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise.
In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
###
Company Contact:
Sanjeev Luther
President & CEO Rafael Pharmaceuticals, Inc.
sanjeev.luther@rafaelpharma.com
Media Contact:
Vanessa Donohue
rafael@antennagroup.com
201-465-8036